Thrombolytic therapy in acute MI. Weighing the risks and benefits

Postgrad Med. 1990 Dec;88(8):79-80, 83-6, 89-90 passim. doi: 10.1080/00325481.1990.11704770.

Abstract

The underlying cause of acute myocardial infarction can now be effectively treated with thrombolytic agents, thereby increasing myocardial salvage and reducing mortality. Clinicians should always be aware of the risk-to-benefit ratio in treating patients with thrombolytic agents and treat each patient on an individual basis.

Publication types

  • Review

MeSH terms

  • Acute Disease
  • Anistreplase / administration & dosage
  • Aspirin / therapeutic use
  • Clinical Trials as Topic
  • Contraindications
  • Heparin / therapeutic use
  • Humans
  • Myocardial Infarction / drug therapy*
  • Streptokinase / administration & dosage
  • Thrombolytic Therapy*
  • Time Factors
  • Tissue Plasminogen Activator / administration & dosage

Substances

  • Anistreplase
  • Heparin
  • Streptokinase
  • Tissue Plasminogen Activator
  • Aspirin